Plasma angiotensin-converting enzyme 2 (ACE2) is a marker for renal outcome of diabetic kidney disease (DKD) (U-CARE study 3)

• Published in: BMJ open diabetes research & care Vol. 12; no. 3; p. e004237
• Main Authors: Ueno, Asami, Onishi, Yasuhiro, Mise, Koki, Yamaguchi, Satoshi, Kanno, Ayaka, Nojima, Ichiro, Higuchi, Chigusa, Uchida, Haruhito A, Shikata, Kenichi, Miyamoto, Satoshi, Nakatsuka, Atsuko, Eguchi, Jun, Hida, Kazuyuki, Katayama, Akihiro, Watanabe, Mayu, Nakato, Tatsuaki, Tone, Atsuhito, Teshigawara, Sanae, Matsuoka, Takashi, Kamei, Shinji, Murakami, Kazutoshi, Shimizu, Ikki, Miyashita, Katsuhito, Ando, Shinichiro, Nunoue, Tomokazu, Wada, Jun
• Format: Journal Article
• Language: English
• Published: England American Diabetes Association 01-05-2024; BMJ Publishing Group LTD; BMJ Publishing Group
• Subjects: Aged; Angiotensin-Converting Enzyme 2 - blood; angiotensins; Biomarkers; Biomarkers - blood; Blood pressure; Creatinine; Diabetes; Diabetic Nephropathies - blood; Diabetic Nephropathies - diagnosis; Diabetic Nephropathies - etiology; diabetic neuropathies; Disease Progression; Endocrine system; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hypertension; Kidney diseases; Male; Middle Aged; Mortality; observational study; outcome assessment, health care; Pathophysiology/complications; Peptidyl-Dipeptidase A - blood; Plasma; Prognosis; Proteins; Urine; diabetic neuropathies; angiotensins; observational study; outcome assessment, health care
• ISSN: 2052-4897; 2052-4897
• DOI: 10.1136/bmjdrc-2024-004237

IntroductionACE cleaves angiotensin I (Ang I) to angiotensin II (Ang II) inducing vasoconstriction via Ang II type 1 (AT1) receptor, while ACE2 cleaves Ang II to Ang (1–7) causing vasodilatation by acting on the Mas receptor. In diabetic kidney disease (DKD), it is still unclear whether plasma or urine ACE2 levels predict renal outcomes or not.Research design and methodsAmong 777 participants with diabetes enrolled in the Urinary biomarker for Continuous And Rapid progression of diabetic nEphropathy study, the 296 patients followed up for 9 years were investigated. Plasma and urinary ACE2 levels were measured by the ELISA. The primary end point was a composite of a decrease of estimated glomerular filtration rate (eGFR) by at least 30% from baseline or initiation of hemodialysis or peritoneal dialysis. The secondary end points were a 30% increase or a 30% decrease in albumin-to-creatinine ratio from baseline to 1 year.ResultsThe cumulative incidence of the renal composite outcome was significantly higher in group 1 with lowest tertile of plasma ACE2 (p=0.040). Group 2 with middle and highest tertile was associated with better renal outcomes in the crude Cox regression model adjusted by age and sex (HR 0.56, 95% CI 0.31 to 0.99, p=0.047). Plasma ACE2 levels demonstrated a significant association with 30% decrease in ACR (OR 1.46, 95% CI 1.044 to 2.035, p=0.027) after adjusting for age, sex, systolic blood pressure, hemoglobin A1c, and eGFR.ConclusionsHigher baseline plasma ACE2 levels in DKD were protective for development and progression of albuminuria and associated with fewer renal end points, suggesting plasma ACE2 may be used as a prognosis marker of DKD.Trial registration numberUMIN000011525.